Nucleai

Next-generation therapeutics require next-generation biomarker strategies. Meet Nucleai at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to see how AI-powered spatial biomarkers and computational pathology are helping biopharma teams move beyond traditional biomarkers toward more precise patient stratification and smarter clinical development decisions. From ADCs and multispecifics to novel IO therapies, spatial intelligence is reshaping how biomarkers are developed, validated, and deployed. 📍 Booth IH01 Book a meeting with our team at ASCO 2026👉https://lnkd.in/gzaYX2xF Avi Veidman | Grainger Greene | Ken Bloom | Byron Lawson | Sharon Elkobi #ASCO26 #SpatialBiology #DigitalPathology #PrecisionMedicine #Biomarkers #AIPathology #spatialbiomarkers #PrecisionOncology

Wrapping up a great poster session at #AACR26. Did you get a chance to stop by our poster? In collaboration with the University of Glasgow, we presented a translational framework in colorectal polyps that bridges high-plex spatial profiling with clinically actionable biomarker strategies. Our approach focuses on turning high-plex mIF data into quantitative spatial insights and practical biomarker outputs—enabling biologically informed patient stratification and more confident drug development decisions. Our poster is now available online 👉https://bit.ly/4crBfbu #spatialbiomarkers, #biomarkers, #precisionmedicine #mIF Ettai Markovits | Grainger Greene

Day 2 in San Diego — momentum is building. 🚀 Our team is here discussing how spatial biomarkers are advancing biomarker strategies for next-generation therapies. Don’t miss our poster tomorrow, in collaboration with the University of Glasgow A Translational Framework for High-Plex Spatial Profiling and Complexity Reduction Toward Diagnostic Assay Development in Colorectal Polyps Abstract 6331/17 | April 21 | 2:00–5:00 PM PT If you’re here, let’s connect https://bit.ly/4czfhCe Ken Bloom | Grainger Greene | Ettai Markovits

Nucleai and Sirona Dx have announced a strategic partnership to deliver an integrated spatial proteomics solution for pharma — connecting tissue to insight in a single engagement. As multiplex imaging technologies advance, the gap between data generation and actionable insight continues to widen. Fragmented workflows across assay development, imaging, and analytics leave substantial biological value unrealized. By combining Sirona Dx’s assay development and validated imaging with Nucleai’s AI-powered spatial analytics, this partnership creates a seamless, end-to-end workflow — from high-quality tissue data to confident biomarker decisions. The joint offering supports applications across oncology, immunology, and neuroscience, including: • Biomarker discovery and validation • Patient stratification • Mechanism of action studies • Clinical trial biomarker programs Read the full announcement 👉https://bit.ly/4sywWjm Meet us at AACR to explore how this integrated approach can support your programs. Book time with our team. 👉https://bit.ly/4cbMHYG #SpatialBiomarkers #SpatialBiology, #DigitalPathology, #PrecisionMedicine, #DrugDevelopment, #ClinicalTrials #Biomarkers, #ComputationalPathology, #AACR26

We'll be at The American Association for Cancer Research Annual Meeting 2026 in San Diego! Join Ken Bloom, Grainger Greene, and Ettai Markovits to discuss how AI-powered spatial analysis is advancing biomarker strategies for next-generation therapies. Explore how our platform turns high-plex mIF data into quantitative spatial insights and clinically actionable biomarkers, enabling biologically informed patient stratification and more confident drug development decisions. Check out our poster presentation in collaboration with the University of Glasgow: A Translational Framework for High-Plex Spatial Profiling and Complexity Reduction Toward Diagnostic Assay Development in Colorectal Polyps Abstract #6331/17 | April 21, 2026 | 2:00–5:00 PM PT 📅 Book a meeting: https://lnkd.in/gzaYX2xF #SpatialBiomarkers #mIF #MultiplexImaging #PrecisionMedicine #AACR26 #DrugDevelopment #Biomarker #CancerResearch #PrecisionOncology #AACR2026

Expression alone does not fully explain response. Spatial analysis of tumor–immune proximity adds critical context beyond PD-L1. Proud to collaborate with Proscia on advancing AI-powered digital pathology.

Biology, like relationships, is complex. Biological systems are shaped by interaction, structure, and spatial context. That’s why we go beyond traditional biomarker scoring to quantify those relationships and inform smarter decisions across next-generation therapeutics. Happy Valentine’s Day from Nucleai 💙 #HappyValentinesDay, #SpatialBiomarkers, #Biomarkers, #PrecisionMedicine, #DigitalPathology, #AIPathology

This World Cancer Day, we’re united by the belief that every patient is unique. Through AI-powered spatial biology, we help advance precision cancer research and diagnostics — one insight at a time. #UnitedByUnique #WorldCancerDay #PrecisionOncology #PrecisionMedicine #Biomarkers #SpatialBiomarkers #SpatialBiology #aipathology #digitalpathology

 📰 New Nature Communications publication ‼️ We’re proud to share a major milestone for Nucleai: our collaborative research has just been published in Nature Portfolio. The study, conducted in collaboration with the The University of Queensland, UQ Frazer Institute, Yale School of Medicine, Wesley Research Institute, Quanterix, and Nucleai, applies multiplexed immunofluorescence and AI-powered spatial analysis to investigate the spatial organization and metabolic characteristics of tumor cells that are associated with response and resistance to immunotherapy in non-small cell lung cancer (NSCLC). As part of the collaboration, Nucleai’s AI-powered mIF analysis enabled scalable, reproducible identification of tumor and immune cell populations, supporting downstream spatial and metabolic analyses. The findings highlight how spatial organization within the tumor microenvironment is closely associated with immunotherapy response in NSCLC. Special thanks to the Nucleai team: Ettai Markovits, Shai Bookstein, Rotem Czertok-Katzir, and the broader Team Nucleai for supporting this work. Congratulations to all co-authors on this important work: James Monkman, Aaron Kilgallon, Clara Lawler, Rafael Tubelleza, Thazin Nwe Aung, Jonathan H. Warrell, Ioannis Vathiotis, Ioannis P. Trontzas, Niki Gavrielatou, Nay Nwe Nyein Chan, Rotem Czertok, Shai Bookstein, Kenneth O'Byrne, Ettai Markovits, David Rimm, and Arutha Kulasinghe. 🔗 Read the PR 👉 https://lnkd.in/g9BV7j9w 🔗 Access the publication 👉 https://lnkd.in/gYTktsnS #Immunotherapy #biomarkers #precisionmedicine #spatialbiomarkers #ImmunoOncology #aipathology #digitalpathology 

HealthIL Week is in full swing, and today our CEO, Avi Veidman took part in the TED Talks segment “From Idea to Impact: AI Success in Pharma” at HealthIL. Avi shared real-world examples of how Nucleai applies AI-powered pathology to support patient selection and de-risk clinical trials, with a focus on ADC programs, alongside fellow Israeli AI-for-pharma startups QuantHealth and DenovAI Biotech. The TED Talks segment followed the AION Labs–led panel, “AI’s Role in the Future of Pharma: From Hype to Value,” which featured speakers from AstraZeneca, Teva Pharmaceuticals, Amazon Web Services (AWS), NVIDIA and A-Squared Ventures Great conversations focused on bringing AI into the clinic and delivering real impact, and we’re proud to take part in this insightful discussion. #HealthIL #AIinPharma #ClinicalTrials #ADC #Pathology #DigitalPathology #Biotech Tal Leibovich-Rivkin | Arnon Horev | Sharon Gour Arie | Dana Bar Or | Anat Boehm-Cagan | Daniel Rabina | Amit Bleweiss | Sam Cronin